Header Logo

Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40?mg/0.4?mL) by autoinjector and prefilled syringe in healthy subjects.

Davidson A, Brimhall D, Kay J, Keystone E, Lee SJ, Kim SH, Bae YJ, Choi EJ, Furst DE. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40?mg/0.4?mL) by autoinjector and prefilled syringe in healthy subjects. Br J Clin Pharmacol. 2021 11; 87(11):4323-4333.

View in: PubMed